rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Failure of oligodendrocyte precursor cells (OPCs) to differentiate and remyelinate axons is thought to be a major cause of the limited ability of the central nervous system to repair plaques of immune-mediated demyelination in multiple sclerosis (MS). Current therapies for MS aim to lessen the immune response in order to reduce the frequency and severity of attacks, but these existing therapies do not target remyelination or stimulate repair of the damaged tissue. Thus, the promotion of OPC differentiation and remyelination is potentially an important therapeutic goal. Previous studies have shown that a recombinant human-derived monoclonal IgM antibody, designated rHIgM22, promotes remyelination, particularly of the spinal cord in rodent models of demyelination. Here, we examined the effects of rHIgM22 in remyelination in the brain using the mouse model of cuprizone-induced demyelination, which is characterized by spontaneous remyelination. The myelination state of the corpus callosum of cuprizone-fed mice treated with rHIgM22 was examined immediately after the end of the cuprizone diet as well as at different time points during the recovery period with regular food, and compared with that of cuprizone-fed animals treated with either vehicle or human IgM isotype control antibody. Mice fed only regular food were used as controls. We demonstrate that treatment with rHIgM22 accelerated remyelination of the demyelinated corpus callosum. The remyelination-enhancing effects of rHIgM22 were found across different, anatomically distinct regions of the corpus callosum, and followed a spatiotemporal pattern that was similar to that of the spontaneous remyelination process. These enhancing effects were also accompanied by increased differentiation of OPCs into mature oligodendrocytes. Our data indicate strong remyelination-promoting capabilities of rHIgM22 and further support its therapeutic potential in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Matsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984
Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity
Nishiyama, A., Komitova, M., Suzuki, R., & Zhu, X. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2495 · Cited by 865
Myelin basic protein: a multifunctional protein
Boggs, J. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6094-7 · Cited by 687
Dicer1 and miR-219 Are Required for Normal Oligodendrocyte Differentiation and Myelination
Dugas, J. C., Cuellar, T. L., Scholze, A., Ason, B., Ibrahim, A., Emery, B., Zamanian, J. L., Foo, L. C., McManus, M. T., & Barres, B. A. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.027 · Cited by 577
The cuprizone animal model: new insights into an old story
Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0591-3 · Cited by 481
Praet, J., Guglielmetti, C., Berneman, Z., Van der Linden, A., & Ponsaerts, P. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.10.004 · Cited by 435
Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned
Gudi, V., Gingele, S., Skripuletz, T., & Stangel, M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00073 · Cited by 430
Animal models of multiple sclerosis: the good, the bad and the bottom line
Ransohoff, R. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3168 · Cited by 379
Mi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21581 · Cited by 300
Multiple Sclerosis: Remyelination in Acute Lesions
Raine, C. S., & WU, E. (1993) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199305000-00003 · Cited by 285
Regional differences between grey and white matter in cuprizone induced demyelination
Gudi, V., Moharregh-Khiabani, D., Skripuletz, T., Koutsoudaki, P. N., Kotsiari, A., Skuljec, J., Trebst, C., & Stangel, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.005 · Cited by 260
Mason, J. L., Toews, A., Hostettler, J. D., Morell, P., Suzuki, K., Goldman, J. E., & Matsushima, G. K. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63726-1 · Cited by 212
Steelman, A. J., Thompson, J. P., & Li, J. (2012) · Neuroscience Research · doi:10.1016/j.neures.2011.10.002 · Cited by 183
Armstrong, R. C., Le, T. Q., Frost, E. E., Borke, R. C., & Vana, A. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08574.2002 · Cited by 178
Xie, M., Tobin, J. E., Budde, M. D., Chen, C.-I., Trinkaus, K., Cross, A. H., McDaniel, D. P., Song, S.-K., & Armstrong, R. C. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e3de90 · Cited by 175
Lindner, M., Heine, S., Haastert, K., Garde, N., Fokuhl, J., Linsmeier, F., Grothe, C., Baumgärtner, W., & Stangel, M. (2008) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00879.x · Cited by 169
Kondo, A., Nakano, T., & Suzuki, K. (1987) · Brain Research · doi:10.1016/0006-8993(87)90499-9 · Cited by 109
In toxic demyelination oligodendroglial cell death occurs early and is FAS independent
Hesse, A., Wagner, M., Held, J., Brück, W., Salinas-Riester, G., Hao, Z., Waisman, A., & Kuhlmann, T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.10.016 · Cited by 98
Abbreviated exposure to cuprizone is sufficient to induce demyelination and oligodendrocyte loss
Doan, V., Kleindienst, A. M., McMahon, E. J., Long, B. R., Matsushima, G. K., & Taylor, L. C. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23174 · Cited by 56
Schmidt, T., Awad, H., Slowik, A., Beyer, C., Kipp, M., & Clarner, T. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9896-0 · Cited by 49
Skripuletz, T., Miller, E., Grote, L., Gudi, V., Pul, R., Voss, E., Škuljec, J., Moharregh-Khiabani, D., Trebst, C., & Stangel, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.009 · Cited by 31
Cited by
The pro-remyelination properties of microglia in the central nervous system
Lloyd, A. F., & Miron, V. E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0184-2 · Cited by 381
Ferroptosis Mediates Cuprizone-Induced Loss of Oligodendrocytes and Demyelination
Jhelum, P., Santos-Nogueira, E., Teo, W., Haumont, A., Lenoël, I., Stys, P. K., & David, S. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1749-20.2020 · Cited by 214
Remyelination in Multiple Sclerosis: Findings in the Cuprizone Model
Leo, H., & Kipp, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416093 · Cited by 46
Glial cells as therapeutic targets in progressive multiple sclerosis
Wilbanks, B., Maher, L., & Rodriguez, M. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1614443 · Cited by 17
Metadata
- Authors
- Mullin, A. P., Cui, C., Wang, Y., Wang, J., Troy, E., Caggiano, A. O., Parry, T. J., Colburn, R. W., & Pavlopoulos, E.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 105
- Pages
- 142-155
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2618929236
- Cited by
- 48
- References
- 24
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.